Shares of Zoetis Inc. (NYSE:ZTS – Get Free Report) have been assigned a consensus rating of “Hold” from the fourteen brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $152.9091.
Several equities analysts recently commented on the company. Piper Sandler reissued a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. UBS Group set a $136.00 price target on Zoetis in a research report on Thursday, January 29th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th.
Check Out Our Latest Research Report on Zoetis
Hedge Funds Weigh In On Zoetis
Zoetis Stock Up 2.4%
Shares of NYSE:ZTS opened at $119.66 on Thursday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis has a 1 year low of $113.29 and a 1 year high of $172.23. The stock has a market capitalization of $50.51 billion, a P/E ratio of 19.88, a PEG ratio of 1.80 and a beta of 0.98. The stock has a 50-day simple moving average of $122.39 and a 200-day simple moving average of $127.49.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the previous year, the business earned $1.40 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts forecast that Zoetis will post 6.07 earnings per share for the current year.
Zoetis Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s payout ratio is 35.22%.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Recommended Stories
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
